bioRxivCancer BiologyPreprint
The protein phosphatase-2A subunit PR130 is linked to cytotoxic protein aggregate formation in mesenchymal pancreatic ductal adenocarcinoma cells
O. H. Kramer, A. Nguyen, A. Leydecker, A.-H. M. Mustafa, J. Murr, F. Butter
Abstract
Protein phosphatase-2A (PP2A) is a major source of cellular serine/threonine phosphatase activity. PP2A B-type subunits regulate the intracellular localization and the catalytic activity of PP2A-A/PP2A-C complexes towards individual proteins. There is limited knowledge on how PP2A B-type subunits regulate biologically important functions and if these subunits determine the growth and drug responsiveness of tumor cells. Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with poor prognosis. Mesenchymal PDAC subtypes are more aggressive and metastasis-prone than epithelial subtypes. We show that mesenchymal PDAC cells express significantly higher levels of the PP2A B-type subunit PR130 and its mRNA Ppp2r3a than epithelial PDAC cells (n=38). Among 17 PP2A B-type subunits, this differential regulation is unique for Ppp2r3a and PR130. The higher levels of PR130 in mesenchymal PDAC cells are linked to their vulnerability to the PP2A inhibitor phendione. Phendione induces apoptosis and an accumulation of cytotoxic protein aggregates in such cells. These processes occur independently of the major tumor suppressor p53, which is frequently mutated in PDAC cells. Proteomic analyses reveal that phendione upregulates the chaperone heat shock protein HSP70 in mesenchymal PDAC cells. Inhibition of HSP70 promotes phendione-induced apoptosis. We additionally disclose that phendione promotes a proteasomal degradation of PR130. Genetic elimination of PR130 sensitizes mesenchymal PDAC cells to phendione-induced apoptosis and protein aggregate formation. These data illustrate pharmacologically amenable, selective dependencies of mesenchymal PDAC cells on PP2A-PR130 and HSP70. PP2A inhibition triggers a harmful accumulation of protein aggregates in neurons. This undesired mechanism might be exploited to kill mesenchymal tumor cells. O_FIG O_LINKSMALLFIG WIDTH=137 HEIGHT=200 SRC="FIGDIR/small/556106v1_ufig1.gif" ALT="Figure 1"> View larger version (40K): org.highwire.dtl.DTLVardef@c8a47forg.highwire.dtl.DTLVardef@a7abfforg.highwire.dtl.DTLVardef@d18a3org.highwire.dtl.DTLVardef@1cc9943_HPS_FORMAT_FIGEXP M_FIG C_FIG HIGHLIGHTS[tpltrtarr] The PP2A subunit PR130 is a molecular marker of mesenchymal PDAC cells [tpltrtarr]The small molecule PP2A inhibitor phendione selectively kills mesenchymal PDAC cells [tpltrtarr]Phendione decreases PR130 through proteasomes and selectively increases the heat shock protein 70 kDa in mesenchymal PDAC cells [tpltrtarr]HSP70 promotes cell survival upon inhibition of PP2A [tpltrtarr]PP2A-PR130 regulates the accumulation of cytotoxic protein aggregates in mesenchymal PDAC cells
- organism: human
- assay: proteomics
- research focus: cell type annotation
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PP2A activation drives aberrant macropinocytosis and cell death in pancreatic ductal adenocarcinoma
Garima Baral, Claire M. Pfeffer, … Brittany L. Allen-Petersen·bioRxiv·Jul 14, 2025
- Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDAC
Claire M. Pfeffer, Sydney J. Clifford, … Brittany L. Allen-Petersen·bioRxiv·Jul 18, 2025
- ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer
Paloma Moreno, Yuuki Ohara, … S Perwez Hussain·bioRxiv·Mar 12, 2024
- Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC
- Arrest-associated transcriptional programmes outweigh apoptosis-associated programmes in treatment-naive pancreatic ductal adenocarcinoma
Chukwuemeka A Obuekwe, Blessing T Ogunoye, … Adewunmi Akingbola·bioRxiv·Nov 6, 2026
- Modulating p38MAPK recalibrates sensitivity of drug-resistant pancreatic adenoductal carcinoma cells toward chemotherapy and correlate with improved outcome in PDAC patients: Experimental and metadata evidence
Vandana Mehra, Khushi Gandhi, … Hridayesh Prakash·bioRxiv·Oct 4, 2025